Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors
NCT02313012
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
19
Enrollment
INDUSTRY
Sponsor class
Conditions
Neoplasm Metastasis
Interventions
DRUG:
CC-90003
Sponsor
Celgene